Amneal Wins Race For US NuvaRing Rival
Immediately Started Commercialization Of Contraceptive
Executive Summary
Amneal has become the first company to secure US approval for, and to launch, a generic alternative to Merck & Co’s top-selling, off-patent NuvaRing contraceptive device in the US. Other generics developers appear to be several months behind.
You may also be interested in...
Amneal Completes Kashiv Takeover
Amneal says it has taken the latest step towards “Amneal 2.0” after completing its deal to acquire Kashiv Specialty Pharmaceuticals.
Amneal Ready To Go Head-To-Head With Mylan’s Xulane In US
Amneal is set to benefit from 180 days of US exclusivity for its norelgestromin and ethinyl estradiol contraceptive patch product after receiving FDA approval with a competitive generic therapy designation. The generic will be the only competitor to Mylan’s Xulane version.
Teva’s Complex Generic Ambitions Number Nearly A Dozen In 2021
Israeli giant Teva is hoping to follow the recent big-ticket launches of generic Truvada/Atripla and NuvaRing with multiple complex generics launches in the US this year. Management discussed individual product opportunities as Teva disclosed full-year financial earnings.